NFL Biosciences SA (ALNFL.PA)
| Previous close | 0.9040 |
| Open | 0.9400 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.8000 - 0.9400 |
| 52-week range | 0.7540 - 5.0000 |
| Volume | |
| Avg. volume | 9,858 |
| Market cap | 4.449M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.90 |
- Globe Newswire
NFL BIOSCIENCES: Decision to approve the issuing of its patent in South Korea
NFL BIOSCIENCES: Decision to approve the issuing of its patent in South Korea NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that it has received approval from the South Korean intellectual property office for issuing its patent (South Korean application no.10-2018-7032224) for NFL-101, a nicotine-free botanical drug candidate comprising natural proteins extracted from tobacco l
- Globe Newswire
NFL BIOSCIENCES: Notice of allowance of its patent in China
NFL BIOSCIENCES: Notice of allowance of its patent in China NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, is announcing that it has received the notice of allowance from the Chinese National Intellectual Property Administration (CNIPA) for issuing its patent (Chinese application no.201780033409.5) for NFL-101, a nicotine-free botanical drug candidate comprising natural proteins extracted fro
- Globe Newswire
NFL Biosciences: 2021 full-year business and earnings update
NFL Biosciences: 2021 full-year business and earnings update Phase II/III clinical trial rolled out for the drug candidate NFL-101 for smoking cessation: first patients recruited and recruitment capacity ramped up Organization further strengthened and active ingredient manufacturing partnership set up Intellectual property extended with an NFL Biosciences patent registered in the United States Co-development agreement signed for the drug candidate NFL-301 to reduce alcohol consumption NFL BIOSCI
